26 Aug 2020 update: The committe has been named and some additional project commentary posted. Go here for details. — Dear All, Following on from the AMR-related funding in the legislation that funded the US government through Sep 2020 (link), the National Academies of Sciences, Engineering, and Medicine (NASEM) is now seeking nominations for an
Dear All, As has been discussed in recent newsletters (link), the UK National Institute for Health and Care Excellence (NICE) and NHS England launched a joint project July 2019 to test a payment model for antibiotic products, based on a product’s value to the NHS, rather than how much is used. This goal of the
Dear All, The June issue of ACS Infectious Diseases (link) is entirely devoted to the perspectives on how we can restore and maintain the antibiotic ecosystem. Check it out … we have perspectives from major groups driving policy, groups doing active R&D, and the major funders. Here’s the table of contents, re-organized slightly to group
Dear All (and with thanks to Damiano for taking the lead on this newsletter): In advance of Italy assuming the G7 Presidency for 2024, The European House – Ambrosetti (an Italian think tank and management consulting firm) published a new report on 15 November 2023 entitled “Value and sustainability of antibiotics as essential tools for the healthcare
Dear All (and with thanks to Kevin for co-authoring), In a clear and compelling policy paper, a dozen of the DRIVE-AB alumni have proposed a concept for a pan-EU/EEA Pull Incentive. To follow the plot, here are the key points as a refresh: To date, the only strong, active Pull model is the UK NHS project that
Note: Be sure to take advantage of the BARDA Industry Day(s) event that occurs Monday-Tuesday of this coming week … see newsletter and forward calendar for details. Dear All, In what could be called Part 2 of Excellent 2023 ASM/ESCMID Talks (read the newsletter on Jen Cohen’s talk on how manufacturing underpins both access and
This newsletter is the first of a series — here are the links to Part 2, Part 3, Part 4, and Part 5. Dear All, Today’s theme is a 3-part journey that could be subtitled “Many are called, but few are chosen,” or “It’s easy to kill bacteria — steam, fire, and bleach are consistently effective —
Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO 2024 PPL. WHO’s webpage about the 2024 PPL. A PowerPoint (.pptx) deck (and there is also a .pdf version) summarizing the new PPL and all prior PPLs. 22 May 2024 post-newsletter
Dear All, As you may remember, last fall I wrote a newsletter about ATMF’s 3rd update to the AMR Benchmark series. You are encouraged to read the report but in brief, the key messages are (i) the pipeline is small with most innovation coming from small biotech, (ii) stewardship and access planning are increasingly seen (but
Dear All, NIAID and RTI International have recently announced the initiation of CC4CARB Chemistry Center for Combating Antibiotic Resistance). In brief, CC4CARB synthesizes compound libraries (free of charge!) based on scaffolds that you propose The focus is on creating novel chemical matter that might have antibacterial activity (there appears to be a focus on Gram-negatives, but there